Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris
Alexion Pharma Canada has entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance for Ultomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder and adult patients with anti-acetylcholine receptor antibody positive generalized myasthenia gravis.
